EPIRUS Biopharma (EPRS) Misses Q2 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
EPIRUS Biopharmaceuticals Reports Second Quarter 2015 Financial Results
August 7, 2015 7:00 AM EDTBOSTON, Aug. 07, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS), a Boston-based, pure-play biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced financial results for the second quarter and six months ended June 30, 2015.
It has been key to our strategy to establish partnerships that align... More
